← ANALYST RATINGS · TIPRANKS
Iovance Biotherapeutics (IOVA): analyst forecast and price target
Analyst consensus
Strong Buy5 Buy1 Hold0 Sell
Ratings of 6 analysts in the last 3 months · top analysts only12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $16.50, the highest $20.00, the lowest $7.00. The average is +21.1% from the last price of $13.62.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $15.00 → $18.00+20.0% | Buy | +32.2% | Reiterated | 13.10.26on TipRanks 04:50 | −0.4%next day −0.9% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $20.00 | Buy | +46.8% | Reiterated | 12.10.26on TipRanks Oct 14 03:30 | −0.4%next day −0.4% | ↗ |
| Colleen M. Kusy★★★★★★★★★★#12105 · hits 35% · avg −6.9% | Robert W. Baird | $6.00 → $11.00+83.3% | Hold | −19.2% | Reiterated | 08.10.26on TipRanks 07:20 | +3.5%next day +9.2% · 5 days +10.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $12.50 → $16.00+28.0% | Buy | +17.5% | Reiterated | 05.10.26on TipRanks 19:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $11.50 → $15.50+34.8% | Hold | +13.8% | Reiterated | 05.10.26on TipRanks 19:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $11.50 → $15.00+30.4% | Hold | +10.1% | Reiterated | 05.10.26on TipRanks 19:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.50 → $16.00+28.0% | Buy | +17.5% | Reiterated | 05.10.26on TipRanks 19:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $11.50 → $15.00+30.4% | Hold | +10.1% | Reiterated | 05.10.26on TipRanks 19:05 | — | |
| Yanan Zhu★★★★★★★★★★#1136 · hits 36% · avg +15.3% | Wells Fargo | $14.00 → $18.00+28.6% | Buy | +32.2% | Assigned | 30.09.26on TipRanks 06:25 | +2.8%next day −4.2% · 5 days −14.8% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $11.50 → $15.00+30.4% | Hold | +10.1% | Reiterated | 30.09.26on TipRanks 03:06 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $20.00 | Buy | +46.8% | Assigned | 30.09.26on TipRanks Sep 29 10:35 | +31.7%next day +2.8% · 5 days −12.3% | ↗ |
| Nicholas Lorusso★★★★★★★★★★#2971 · hits 56% · avg +39.7% | TD Cowen | $10.00 → $16.00+60.0% | Buy | +17.5% | Reiterated | 29.09.26on TipRanks 10:10 | +31.7%next day +2.8% · 5 days −12.3% | ↗ |
| Andrea Newkirk★★★★★★★★★★#2841 · hits 50% · avg +29.4% | Goldman Sachs | $15.00 | Buy | +10.1% | Initiated | 24.09.26on TipRanks 03:20 | +6.1%next day +1.3% · 5 days +32.2% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $4.00 → $7.00+75.0% | Hold | −48.6% | Assigned | 20.08.26on TipRanks 06:11 | +13.4%next day −8.2% · 5 days −9.2% | ↗ |
| Salim Syed★★★★★★★★★★#7609 · hits 44% · avg +0.2% | Mizuho Securities | $10.00 → $11.00+10.0% | Buy | −19.2% | Reiterated | 17.08.26on TipRanks 12:30 | +2.2%next day −0.3% · 5 days +14.7% | ↗ |
| Reni Benjamin★★★★★★★★★★#12340 · hits 34% · avg −9.2% | Citizens JMP | $5.00 → $8.00+60.0% | Buy | −41.3% | Reiterated | 07.08.26on TipRanks 06:25 | +1.5%next day +1.0% · 5 days +9.7% | ↗ |
| Geulah Livshits★★★★★★★★★★#2175 · hits 35% · avg +7.2% | Chardan Capital | $14.00 | Buy | +2.8% | Reiterated | 07.05.26on TipRanks 20:15 | +1.1%next day +2.0% · 5 days −4.9% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | — | Hold | — | Reiterated | 25.02.26on TipRanks 08:00 | +0.5%next day −0.5% · 5 days +12.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Iovance Biotherapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.89 at a price of $14.82 (−13.0%); now: $14.40 at $13.62 (+5.7%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 10 | 8 | 5 | 2 | 1 |
| Buy | 1 | 1 | 1 | 3 | 9 | 11 |
| Hold | 1 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.09 (from $-0.10 to $-0.07). Last quarter: $-0.11.
Sales
Next quarter’s sales estimate — $116M (from $110M to $119M). Last quarter: $99M.
Best top-analyst consensus in the sector · Healthcare
About Iovance Biotherapeutics
- CEO: Frederick G. Vogt
- Employees: 975
- 825 Industrial Road, San Carlos, CA, 94070, US
- www.iovance.com
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Data from the stock’s TipRanks forecast page, read 0 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗